Brainstorm Cell Therapeutics Inc. is a New York-based biotech company that develops and commercializes cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn cell therapy platform uses cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors and modulate disease processes. Brainstorm Cell Therapeutics Inc. has completed phase III clinical trial of NurOwn for amyotrophic lateral sclerosis and phase II trial for multiple sclerosis and Alzheimer's disease.